Antisense oligonucleotides: treating neurodegeneration at the level of RNA.
Ontology highlight
ABSTRACT: Adequate therapies are lacking for Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and other neurodegenerative diseases. The ability to use antisense oligonucleotides (ASOs) to target disease-associated genes by means of RNA may offer a potent approach for the treatment of these, and other, neurodegenerative disorders. In modifying the basic backbone chemistry, chemical groups, and target sequence, ASOs can act through numerous mechanisms to decrease or increase total protein levels, preferentially shift splicing patterns, and inhibit microRNAs, all at the level of the RNA molecule. Here, we discuss many of the more commonly used ASO chemistries, as well as the different mechanisms of action that can result from these specific chemical modific
SUBMITTER: DeVos SL
PROVIDER: S-EPMC3701770 | biostudies-literature | 2013 Jul
REPOSITORIES: biostudies-literature
ACCESS DATA